presenter：prof. quanyin hu (university of wisconsin-madison)
topic：engineering cells for cancer immunotherapy
time：3:00 pm, march 28th (friday)
location:909-b
abstract:
as important biological entities and natural carriers for proteins and molecules, endogenous cells with low immunogenicity and toxicity have attracted considerable attention for biomedical applications and have achieved encouraging progress, especially as therapeutics and delivery carriers. the convergence of multiple disciplines has equipped cell engineering with control over their spatiotemporal distribution to enhance treatment efficacy and reduce side effects. in this talk, i will introduce our ongoing efforts in engineering endogenous cells for various biomedical applications with a particular focus on cancer immunotherapy.
biography：
dr. quanyin hu is a vilas associate professor at the school of pharmacy, university of wisconsin-madison (uw-madison). he received his ph. d. degree in biomedical engineering at the university of north carolina at chapel hill (unc-ch) and north carolina state university from 2014-2018. before he joined uw-madison, he was a postdoc associate at the koch institute for integrative cancer research at the massachusetts institute of technology (mit) from 2018-2020. dr. hu is currently serving as the associate editor for the journal of nanobiotechnology, young star editor for nano research, and guest editor for bioactive materials. he has published more than 90 research papers, including nature biotechnology, nature nanotechnology,nature biomedical engineering, nature review bioengineering,science translational medicine, science advances, and nature communications, with over 16,000 citations. dr. hu is recognized as nci r01 awardee, nibib r01 awardee, nibib trailblazer, american cancer society (acs) research scholar, v foundation scholar, the mit innovators under 35 (tr35) china, the 2023 bmes-cmbe rising star junior faculty, 2023 journal of nanobiotechnology rising star, 2022 icanx young scientist, uw madison early career innovator, clarivate highly cited researcher (2022-2024), young investigator from many societies and foundations, emerging investigator from many journals.
contact：qian chen